You can buy or sell BSX and other stocks, options, ETFs, and crypto commission-free!
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg. Read More The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease, and other cardiovascular disorders including structural heart conditions. The Rhythm Management segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal, and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
52 Week High
52 Week Low
Yahoo FinanceMar 19
Boston Scientific (BSX) Rides on Acquisitions, Innovation
On Mar 18, we issued an updated research report on Boston Scientific Corporation BSX. The company’s recent acquisitions have added various products (though many are under development) with immense potential to its portfolio.
Yahoo FinanceMar 19
Boston Scientific's EP Arm Gets a Lift From Study Success
Boston Scientific Corporation BSX has moved a step ahead with its Electrophysiology business on the latest positive outcome related to the company’s LUMINIZE RF (Radiofrequency) Balloon Catheter.
Yahoo FinanceMar 18
BofA Lowers Boston Scientific Revenue Estimates On FDA Warning, But Keeps Buy Rating
A Food and Drug Administration warning about possible dangers from balloons and stents coated with the drug paclitaxel is bad news for Boston Scientific Corporation (NYSE: BSX)’s Eluvia stent, but Bank of America Merrill Lynch is still recommending the stock on the basis of the company’s broad overall portfolio.
Expected Apr 24, Pre-Market